Multiple Endodermal Organoid Generation from Robustly Amplified Human Posterior Gut Progenitors
Project/Area Number |
15H06534
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
General surgery
|
Research Institution | Yokohama City University |
Principal Investigator |
ZHANG Ranran 横浜市立大学, 医学研究科, 博士研究員 (10760887)
|
Research Collaborator |
Taniguchi Hideki
Takebe Takanori
|
Project Period (FY) |
2015-08-28 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 幹細胞 / 原始腸内胚葉細胞 / 分化 / 肝臓 / 移植 / PGEC / liver bud / transplantation / pancreas / differentiation / liver / pancreatic / intestine / 多能性幹細胞 / 分化誘導 / 内胚葉細胞 |
Outline of Final Research Achievements |
Early human developmental progenitors naturally possess robust amplification potential to ensure organ growth; thereby, are considered as a promising source for therapy due to minimal risks for tumor or ectopic tissue formation. Here, we first demonstrated the reproducible generation of human CDX2+ posterior gut endoderm cells (PGECs) from multiple induced pluripotent stem cell (iPSC) clones. We were able to amplify storable PGECs over a number of passages up to 1021 cells, showed much more stable differentiation propensity into endodermal lineage cells. Furthermore, human PGECs were capable of producing hepatic and intestinal tissues. PGEC-liver organoid transplantation showed therapeutic potential in treating lethal liver failure. Thus, the use of PGECs may be not only a promising alternative therapeutic source of pluripotency for self-organizing endodermal organoids but also a unique approach to study the developmental biology and disease model of the human gut.
|
Report
(3 results)
Research Products
(4 results)